Evelo Biosciences: Rises on positive data from eczema drug study

Evelo Biosciences

09/12/2020 13:17

** Biotech co's shares  EVLO.O  rise 14.5% to $6 premarket
    ** Company reports positive data from its early-stage study
of EDP1815, its oral medicine to treat patients with mild to
moderate atopic dermatitis, also known as eczema  urn:newsml:reuters.com:*:nGNE2MDq8b
    ** Says drug was well-tolerated with no serious adverse
events
    ** For the fourth time in clinical trials, co observed
reduced systemic inflammation
    ** Expects to share complete dataset from study in early
2021     
    ** EVLO is up ~29% YTD
    

 (Reporting by Vishwadha Chander in Bengaluru)
 ((Vishwadha.Chander@thomsonreuters.com; outside U.S. +91
7506036802;))